Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAVITI: Guselkumab Induction Therapy in Moderately to Severely Active Crohn's Disease
jRCT2031210678Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial of guselkumab in Crohn's disease (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Clinical remission at Week 12 and Endoscopic response at Week 12. Started Oct 2022; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2031210678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210678.